COLLABORATIONS AND ALLIANCES (Detail Textuals 2) (USD $)	3 Months Ended		12 Months Ended	1 Months Ended			3 Months Ended		51 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2011	Jan. 31, 2013 Daiichi Sankyo Tivantinib Agreement	Feb. 28, 2011 Daiichi Sankyo Tivantinib Agreement	Dec. 31, 2008 Daiichi Sankyo Tivantinib Agreement	Mar. 31, 2013 Daiichi Sankyo Tivantinib Agreement	Mar. 31, 2012 Daiichi Sankyo Tivantinib Agreement	Mar. 31, 2013 Daiichi Sankyo Tivantinib Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront licensing payment						$ 60,000,000
Additional potential development and sales milestone payments						560,000,000
Cumulative share of Phase 3 collaboration costs									70,400,000
Milestone payment received				15,000,000	25,000,000		15,000,000
Cumulative share of Phase 3 collaboration costs in excess of milestones amounts received							30,400,000
Amount recognized as contra-revenue and netted against our tivantinib Daiichi Sankyo research and development revenue							200,000	900,000
Non-refundable share of advance drug purchases recognized as contra-revenue								2,500,000
Notice period for termination of contract prior to start of specified period							90 days
Notice period for termination of contract Post start of Phase 3 clinical trials							180 days
Research and development revenue	5,661,000	8,498,000	47,310,000				1,900,000	1,300,000
Deferred Revenue							$ 18,700,000		$ 18,700,000